Free Trial
→ Trump’s issues shocking Executive Order on U.S. Dollar (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ORGS

Orgenesis Q3 2023 Earnings Results & Report

Orgenesis logo
$0.0004 -0.07 (-99.43%)
As of 11:07 AM Eastern

Orgenesis reported Q3 2023 earnings on November 13, 2023. The company reported EPS of -$4.30, while revenue was $0.11 million.

Research:Profile

Earnings Announcement Details

Quarter
Q3 2023
Report Date

Orgenesis EPS Results

Actual EPS
-$4.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Orgenesis Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Orgenesis' next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules.

Conference Call Resources

Orgenesis Q3 2023 Earnings FAQ

Orgenesis (NASDAQ:ORGS) reported earnings of -$4.30 per share for Q3 2023. The report was announced on Monday, November 13, 2023.

Orgenesis reported revenue of $0.11 million for Q3 2023.

Orgenesis' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Orgenesis on the company's earnings history page.

Orgenesis Earnings Headlines

Orgenesis (NASDAQ:ORGS) Stock Falls 5.2% - Here's What Happened
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31089949
Orgenesis Shareholders Approve Major Charter and Stock Increase
June 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ORGS/pressreleases/2292841/orgenesis-shareholders-approve-major-charter-and-stock-increase/
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.tc pixel
October 14 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Orgenesis Issues Alpha Warrant in New Financing Deal
January 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-issues-alpha-warrant-in-new-financing-deal?utm_source=marketbeat.com&utm_medium=referral
Orgenesis Subsidiary Secures Convertible Loan Agreement
September 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-subsidiary-secures-convertible-loan-agreement?utm_source=marketbeat.com&utm_medium=referral
Orgenesis Director Ashish Nanda Resigns
August 25, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-director-ashish-nanda-resigns?utm_source=marketbeat.com&utm_medium=referral
See More Orgenesis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orgenesis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orgenesis and other key companies, straight to your email.

About Orgenesis

Orgenesis (NASDAQ:ORGS) is a biotechnology company focused on developing and enabling cell and gene therapies. The company works on autologous cell therapies, which use a patient’s own cells, and on technologies designed to support the processing, manufacturing and delivery of these therapies.

Its activities include the development of proprietary therapeutic programs and the Orgenesis POCare platform. POCare is intended to provide decentralized, point-of-care capabilities for cell and gene therapy manufacturing, helping clinical and healthcare sites produce treatments closer to the patient under controlled processes.

Orgenesis was founded in 2011 and has pursued partnerships and operations across the United States, Europe and Israel. Vered Caplan, a co-founder of the company, has served as its chief executive officer. The company’s work combines therapeutic development with manufacturing infrastructure intended to support broader adoption of advanced cell and gene therapies.

View Orgenesis Profile
Earnings Tools